Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LOS ANGELES--(BUSINESS WIRE)--Meditope Biosciences, Inc., a biotechnology company developing antibody-based cancer products, today announced it has raised $3.6 million in Series A funding from angel investors to advance its proprietary monoclonal antibody (mAb) linker technology platform.
Help employers find you! Check out all the jobs and post your resume.
LOS ANGELES--(BUSINESS WIRE)--Meditope Biosciences, Inc., a biotechnology company developing antibody-based cancer products, today announced it has raised $3.6 million in Series A funding from angel investors to advance its proprietary monoclonal antibody (mAb) linker technology platform.
Help employers find you! Check out all the jobs and post your resume.
